ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3246

Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry

Kathleen Kolstad1, Shufeng Li2, Virginia D. Steen3 and Lorinda Chung4, 1Rheumatology, Stanford Univeristy, Stanford, CA, 2Dermatology, Stanford University, Stanford, CA, 3Rheumatology, Georgetown University Medical Center, Washington, DC, 4Rheumatology, Stanford University Medical Center, Palo Alto, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: outcomes, pulmonary complications and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics III

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose:  Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). Predictors of short-term mortality include male sex, age>60 years, functional class IV, and lung diffusing capacity (DLCO) <39% (1). The purpose of this study was to identify independent predictors of long-term outcomes.

Methods:  Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry is a prospective registry of SSc patients at high risk for PAH or with definite PH based on right heart catheterization within six months of enrollment. World Health Organization Group I PAH patients were included (using the strict criteria of baseline pulmonary artery pressure (PAP) >= 25 mmHg, pulmonary capillary wedge pressure <=15 mmHg, and forced vital capacity >= 65%). Baseline characteristics, time to clinical worsening (TTCW), and cause of death in the short (<1 year), medium (1-4.9 years) and long (>=5 years) term were assessed. TTCW was defined as time to death, PAH-related hospitalization, lung transplantation, parenteral prostacyclin treatment, or worsening symptoms (decrease of >15% in the 6-minute walk distance (6MWD) and worsening of functional class andaddition of PAH-specific medication). Cox proportional hazard models were used to identify the predictors of overall survival and TTCW.

Results:  A total of 167 SSc-associated PAH patients were included. The patient population was predominantly Caucasian (80%), female (90%), and had limited cutaneous SSc (72%). The 1, 3, 5, and 8-year cumulative survival rates were 95%, 76%, 64%, and 50%, respectively. The majority of patient deaths in the short and medium term were due to PAH (62% and 60%, respectively), while in the long-term were due to causes unrelated to SSc (75%), including cancer (n=2), infection (n=1), cerebrovascular disease (n=1), sudden death (n=1), and unknown (n=1). Baseline 6MWD >165 m (HR 0.38 95% CI 0.16-0.88) and % predicted DLCO >40 (HR 0.45 95% CI 0.23-0.89) were predictors of long-term survival on multivariate analysis. The median TTCW was 4.15 years (95% CI 3.07-5.94). At 1, 3, 5, and 8 years the percentage of patients meeting criteria for clinical worsening was 23%, 40%, 57%, and 70%, respectively. Mean PAP (mPAP) >34 mmHg (HR 2.09 95% CI 1.16-3.79) and pulmonary vascular resistance (PVR) >4.76 WU (HR 2.04 95% CI 1.14-3.68) were predictive of progression to clinical worsening.

Conclusion:  This is the longest-term prospective study to date evaluating outcomes in a US based multi-center cohort of patients with SSc-associated PAH. These data suggest that if PAH is well-controlled in the first several years after diagnosis, SSc patients have favorable outcomes, and typically die of causes unrelated to SSc. PVR and mPAP can predict progression to clinical worsening while 6MWD and % predicted DLCO values at the time of diagnosis predict long-term survival in this population. Reference: Chung L et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res. 2014 66(3): 489–95.


Disclosure: K. Kolstad, None; S. Li, None; V. D. Steen, None; L. Chung, Gilead, 5,Cytori, 5,Reata, 5,United Therapeutics, 2.

To cite this abstract in AMA style:

Kolstad K, Li S, Steen VD, Chung L. Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/predictors-of-long-term-outcomes-in-systemic-sclerosis-associated-pulmonary-arterial-hypertension-from-the-pulmonary-hypertension-assessment-and-recognition-of-outcomes-in-scleroderma-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-long-term-outcomes-in-systemic-sclerosis-associated-pulmonary-arterial-hypertension-from-the-pulmonary-hypertension-assessment-and-recognition-of-outcomes-in-scleroderma-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology